AUSTRALASIAN DIABETES CONGRESS 2018

Industry Hosted Breakfast Symposium 

Wednesday, 22 August 2018

Sanofi hosted Breakfast Symposium –

This breakfast is booked out.

Hosted and supported by

SANOFI

Date: Wednesday, 22 August 2018
Time: 6.45am for 7am start – 8am
Room: Riverbank 6
Title: The Changing Face of Type 1 Diabetes – What does the Future Hold?
Chair: A/Prof Stephen Stranks – Director of Southern Adelaide Diabetes & Endocrine Services and Associate Professor, Flinders University
Speaker/s:
Dr Spiros Fourlanos – Royal Melbourne Hospital
Dr Sarah Glastras – Royal North Shore Hospital
Cost: There is no cost to attend, however you must indicate this in your registration.
Summary:
Rates of overweight, obesity and metabolic syndrome are rising in adults with T1D, which adversely impact glycaemic control and increase micro and macrovascular risk (1, 2). With advances in our understanding of the complexities in the subtypes and diagnosis of diabetes, diverse therapeutic strategies are required.  The symposium will address the evolving challenges facing contemporary management and discuss pathways which may be potential targets for the future therapies in adult patients with T1D.

The symposium will conclude with a panel discussion where questions from the audience will be welcomed.

BD hosted Breakfast Symposium

This breakfast is booked out.

Hosted and supported by

BD

DateWednesday, 22 August 2018
Time6.45am for 7am start – 8am
Room: City 1 & 2

Title: “Detecting, Treating and Preventing Lipohypertrophy”
Speaker/s: Michelle Robins
Cost: There is no cost to attend, however you must indicate this in your registration.
Summary: The workshop will teach participants HOW to detect lipohypertrophy using a hands-on, step-wise approach with the aid of a lipohypertrophy education tool. Participants will be provided with a hard copy handout detailing how to document, treat, and prevent lipohypertrophy in patients who inject their diabetes medication.

Michelle is a Credentialed Diabetes Educator with 25 years’ experience in many aspects of diabetes care and education, and is currently employed as a Nurse Practitioner in Melbourne.  Her past employment, as a Diabetes Educator, has included major tertiary hospital settings – including St Vincent’s Hospital Melbourne, Melbourne Division of General Practice, Melbourne Extended Care and Rehabilitation Service, and Logan/Beaudesert Health Service in Queensland.  Michelle has served on more than 40 diabetes-related committees, written book chapters and is consistently highly evaluated in her teaching role.

iNova Pharmaceuticals hosted Breakfast Symposium

This breakfast is booked out.

Hosted and supported by

inova

DateWednesday, 22 August 2018
Time6.45am for 7am start – 8am
Room: Riverbank 5

Title: “Obesity – to treat or not to treat?”
Speaker/s:
Professor Michael Cowley – Professor of Physiology, Monash University
Associate Professor Samantha Hocking – Endocrinologist, University of Sydney
Professor Stephen Colagiuri – Director of The Boden Institute at the University of Sydney
Cost: There is no cost to attend, however you must indicate this in your registration.
Summary: The session, targeted at Endocrinologists, is proposed as a series of three 20 minute talks covering topics such as:

  1. Why is obesity so difficult to treat? (To focus on the scientific basis of the chronic, relapsing nature of obesity)
  2. Advances in pharmacologic interventions – where are we now?
  3. Obesity Management – Why is it not in the diabetes management algorithm?

Ypsomed Australia hosted Breakfast Symposium

Hosted and supported by

YPSOMED

Date: Wednesday, 22 August 2018
Time: 6.45am for 7am start – 8am
Room: Riverbank 7 & 8
Title: A little extra choice – Real-world experiences with the mylife™ YpsoPump®
Speaker/s: To be confirmed
Cost: There is no cost to attend, however you must indicate this in your registration.
Summary: The panel will comprise a mix of people who have experience using the mylife™ YpsoPump®.  This symposium will provide you with the latest information about the mylife™ YpsoPump® system, including local product updates and clinical perspectives.

The session will incorporate:

  • A current update on the mylife™ YpsoPump® system in Australia
  • Status of the mylife™ Neva BGM and integration with the mylife™ App
  • An endocrinologist’s viewpoint on the real-world reporting applications and clinical experiences with mylife™ YpsoPump®.

Thursday, 23 August 2018

Sanofi hosted Breakfast Symposium –

 This breakfast is booked out.

Hosted and supported by

SANOFI

Date: Thursday, 23 August 2018
Time: 6.45am for 7am start – 8am
Room: E1
Title: Hypoglycaemia, its underlying impact on insulin optimisation & the role of Toujeo®
Chair: : Prof John Prins – CEO of Mater Research, Senior Staff Endocrinologist at Princess Alexandra Hospital
Speaker/s:
Prof Jonathan Shaw – Baker IDI
Dr Ted Wu – Royal Prince Alfred Hospital
Prof David Simmons – Campbelltown Hospital
Cost: There is no cost to attend, however you must indicate this in your registration.
Summary: Through the assistance of continuous glucose monitoring, we have a greater understanding of hypoglycaemia prevalence and the subsequent adverse effects that this may cause patients with both type 1 and type 2 diabetes. Insulin remains a critical tool in the management of diabetes; however, its propensity to cause hypoglycaemia can result in a myriad of behaviours for patients either commencing therapy or for those who have experienced episodes that may hinder good glycaemic control.

Toujeo® (insulin glargine 300 units/mL) is a development in basal insulin analogues that offers reduced variability and a greater duration of action than its predecessor Lantus® (insulin glargine 100 units/mL) with a corresponding reduction in hypoglycaemia rates in type 2 diabetes. This symposium will provide insight into the role and value of Toujeo® for patients and clinicians in Australia.

The symposium will conclude with an expert panel for attendees to pose questions to the speakers.

Topic 1: What is “Fear of Hypoglycaemia” and how real is it for patients on insulin?

Topic 2: Hypoglycaemia and cardiovascular outcomes – what do we know?

Topic 3: What benefits can Toujeo® (insulin glargine 300 units/mL) provide beyond HbA1c?

Bi-Lilly hosted Breakfast Symposium

Hosted and supported by

Date: Thursday, 23 August 2018
Time: 6.45am for 7am start – 8am
Room: City 1 & 2
Title: Update on type 2 diabetes medications, cardiovascular outcome trials, and reducing cardiovascular risk in patients with type 2 diabetes
Speaker/s:
A/Prof Stephen Stranks – Director of Southern Adelaide Diabetes & Endocrine Services and Associate Professor, Flinders University
A/Prof Matthew Worthley – Royal Adelaide Hospital, A/Prof at the University of Adelaide
Cost: There is no cost to attend, however you must indicate this in your registration.
Summary: A/Prof Steve Stranks and A/Prof Matthew Worthley will walk you through the latest CVOT data for type 2 diabetes medications and how these studies should be driving a new thought process in type 2 diabetes management.

Lilly hosted Breakfast Symposium

Hosted and supported by

Lilly

Date: Thursday, 23 August 2018
Time: 6.45am for 7am start – 8am
Room: E2 & E3
Title: Rethinking initial injectable therapy for people with Type 2 Diabetes: GLP-1s or Basal Insulin?
Speaker/s:
Dr. Samantha Hocking
Dr. Mark Kennedy
Ms. Bernadette Heenan
Cost: There is no cost to attend, however you must indicate this in your registration.
Summary:
The recently released (draft) ADA-EASD consensus guidelines for the Management of Hyperglycaemia in Type 2 Diabetes recommend GLP-1RA as the preferred initial injectable therapy to insulin.

This symposium will review the evidence supporting these recommendations from the perspective of the:

  • Endocrinologist
  • General Practitioner
  • Diabetes Nurse Educator

Join us for an interactive discussion on this important update to the clinical practice guidelines with our outstanding panel of speakers. There will be ample time to discuss the changes, address your questions and learn from these experts about ways in which you can incorporate these changes into your clinical practice.

Novo Nordisk hosted Breakfast Symposium

This breakfast is booked out.

Hosted and supported by

Date: Thursday, 23 August 2018
Time: 6.45am for 7am start – 8am
Room: Riverbank 7 & 8
Title: The need for innovations in insulin and Ryzodeg® 70/30 – a new co-formulation insulin!
Chair/s: Prof Richard MacIsaac
Speaker/s:

  1. The need for innovations in insulin: Scientific update – Presented by Prof Steven Kahn
  2. Clinical overview of Ryzodeg® 70/30 – Presented by Prof Tim Davis;
  3. Clinical experience with Ryzodeg® 70/30 – Presented by Dr Sarah Glastras & Prof Tim Davis

Cost: There is no cost to attend, however you must indicate this in your registration.
Summary:
With the ever changing landscape of Type 2 Diabetes (T2D) management, this symposium will provide insights into current T2D issues, and discuss the need for new insulins to improve both glycaemic control and reduce the frequency of hypoglycaemia.

Novo Nordisk is excited to share with you updates in its portfolio of insulins, with the recent Therapeutic Goods Administration (TGA) approval of Ryzodeg® 70/30.
Ryzodeg® 70/30 is a soluble co-formulation of two distinct insulin analogues in the ratio of 70% ultra-long-acting insulin degludec (IDeg) and 30% rapid-acting insulin aspart (IAsp). This breakfast symposium will provide attendees with a balanced overview of the Ryzodeg® 70/30 clinical trial programme and share the early in-clinic experience with Ryzodeg® 70/30 in Australia. It will also provide practical considerations when starting patients on Ryzodeg® 70/30.